Domestic target anti-tumor drug LAG-3! China Phase I clinical study of Xinda biological monoclonal antibody ibi110 completed the first case of Drug Administration

December 7, 2019 news / BIOON / -- innovent biologics is a biopharmaceutical company dedicated to R & D, production and sales of innovative drugs for the treatment of major diseases such as tumor, autoimmune and metabolic diseases Recently, the company announced that its phase I clinical study of recombinant all human anti lymphocyte activating gene 3 (LAG-3) monoclonal antibody (R & D Code: ibi110) has completed the first patient administration in China The study (cibi110a101) is an evaluation of ibi110 in China The primary purpose of the IA / IB phase clinical study in patients with advanced cancer was to evaluate the safety, tolerance and antitumor activity of ibi110 alone or in combination with Dabusu ® (recombinant all human anti-PD-1 monoclonal antibody, English trademark: tyvyt ®, common chemical name: cindilimab injection) in patients with advanced cancer Among them, stage IA is the study to evaluate the safety, tolerance and effectiveness of single drug ibi110 Ibi110, a recombinant all human monoclonal antibody against LAG-3, is expected to provide a new clinical solution for patients Ibi110 can block the interaction between LAG-3 and MHCII by directly binding with LAG-3 on T cells, relieve the inhibition of LAG-3 on T cell activation, and enhance the anti-tumor immune response of T cells At the same time, ibi110 and PD-1 / PD-L1 antibody drugs are expected to enhance the immune response and anti-tumor effect Professor Zhou caicun, director of Oncology Department of Shanghai Pulmonary Hospital, pointed out: "although immunosuppressive agents have shown gratifying efficacy in the treatment of a variety of tumors, they still face many new challenges With the increasing popularity of anti-PD-1 / PD-L1 antibody in tumor therapy, some patients who are resistant to PD-1 / PD-L1 therapy have appeared in clinical practice At the same time, the therapeutic effect of anti-PD-1 / PD-L1 therapy in the primary patients also needs to be further improved Therefore, it is of great clinical significance to develop the next generation of tumor immunodrugs LAG-3 is one of the most promising and potential targets in tumor immunotherapy We are very looking forward to the clinical research results of ibi110 " Dr Zhou Hui, vice president of medical science and strategic Oncology Department of Xinda biopharmaceutical group, said: "LAG-3 is an important immunosuppressive receptor At present, there is no antibody drug for LAG-3 target approved for market A number of early clinical studies have been carried out in foreign countries The preliminary results show that as a single drug therapy or combined with PD-1 / PD-L1 antibody drugs, targeted LAG-3 shows certain safety and anti-tumor activity, especially the combined therapy is expected to play a synergistic role Therefore, the development of drugs targeted at LAG-3 will provide patients with newer, comprehensive and effective treatment options We hope to evaluate the potential clinical value of ibi110 and its combination therapy as soon as possible, so that more patients can benefit from it " Ibi110 is the original IgG4 κ recombinant all human anti lymphocyte activating gene 3 (LAG-3) monoclonal antibody developed by Xinda biopharmaceutical It belongs to the first class of innovative drugs It can directly combine with LAG-3, block the interaction between LAG-3 and MHCII, activate and enhance the anti-tumor effect of T cells, and improve the anti-tumor effect in cooperation with PD-1 / PD-L1 antibody drugs Ibi110 is expected to play an anti-tumor activity in the form of single drug or combined with PD-1 / PD-L1 antibody drugs, delay the occurrence of drug resistance, and provide a more effective treatment scheme for the majority of cancer patients Source: Xinda biology